Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses.
SARS-CoV-2
adaptive immunity
animal models
antiviral treatment
nirmatrelvir
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
revised:
27
02
2023
received:
15
02
2023
accepted:
02
03
2023
medline:
9
5
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the risk of progression to severe COVID-19. However, the impact of nirmatrelvir treatment on the development of SARS-CoV-2-specific adaptive immune responses is unknown. Here, by using mouse models of SARS-CoV-2 infection, we show that nirmatrelvir administration blunts the development of SARS-CoV-2-specific antibody and T cell responses. Accordingly, upon secondary challenge, nirmatrelvir-treated mice recruited significantly fewer memory T and B cells to the infected lungs and mediastinal lymph nodes, respectively. Together, the data highlight a potential negative impact of nirmatrelvir treatment with important implications for clinical management and might help explain the virological and/or symptomatic relapse after treatment completion reported in some individuals.
Identifiants
pubmed: 36946379
doi: 10.15252/emmm.202317580
pmc: PMC10165354
doi:
Substances chimiques
nirmatrelvir
7R9A5P7H32
Antiviral Agents
0
Lactams
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17580Informations de copyright
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Nat Commun. 2020 Sep 4;11(1):4417
pubmed: 32887884
Mol Ther. 2022 Jan 5;30(1):311-326
pubmed: 34547465
Nature. 2019 Oct;574(7777):200-205
pubmed: 31582858
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):629-34
pubmed: 18184798
Sci Immunol. 2016 Oct 21;1(4):
pubmed: 27868108
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349
pubmed: 35653428
Med. 2021 Mar 12;2(3):243-262.e8
pubmed: 33521747
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Clin Infect Dis. 2023 Feb 8;76(3):e537-e539
pubmed: 35698452
JCI Insight. 2022 Dec 22;7(24):
pubmed: 36378539
Sci Immunol. 2022 Feb 25;7(68):eabi6112
pubmed: 35213210
EMBO Mol Med. 2023 May 8;15(5):e17580
pubmed: 36946379
J Med Chem. 2016 Jul 28;59(14):6595-628
pubmed: 26878082
Nat Immunol. 2004 Aug;5(8):809-17
pubmed: 15247915
Nature. 2022 Mar;603(7902):693-699
pubmed: 35062016
Acta Pharmacol Sin. 2023 Jan;44(1):255-257
pubmed: 35773339
Nature. 2022 May;605(7908):146-151
pubmed: 35314834
Cell Res. 2020 Aug;30(8):678-692
pubmed: 32541865
Nat Immunol. 2020 Mar;21(3):321-330
pubmed: 32066949
ACS Pharmacol Transl Sci. 2021 Mar 11;4(3):1096-1110
pubmed: 35287429
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Int J Mol Sci. 2021 Oct 29;22(21):
pubmed: 34769210
Sci Immunol. 2022 Jan 28;7(67):eabl9929
pubmed: 34812647
J Med Chem. 2022 Feb 24;65(4):2716-2746
pubmed: 33186044
N Engl J Med. 2022 Sep 15;387(11):1045-1047
pubmed: 36069968
Clin Infect Dis. 2023 Feb 8;76(3):e526-e529
pubmed: 35737946
Immunity. 2021 Sep 14;54(9):2089-2100.e8
pubmed: 34469774
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
J Immunol. 2000 Dec 15;165(12):6833-9
pubmed: 11120806
J Immunol. 2004 Nov 1;173(9):5679-87
pubmed: 15494519
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481